- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07946666
A Clinical Trial to Evaluate the Effects of the Synbiotic Dual Cap® on Gastrointestinal Comfort in Adults Initiating GLP-1 or Dual-Incretin Therapy for Weight Loss.
This is a decentralized, single-group, open-label clinical trial evaluating the effects of the Synbiotic Dual Cap® in 40 adults who have initiated GLP-1 or dual-incretin therapy within the preceding 60 days and who are experiencing at least one associated gastrointestinal symptom. All participants will receive the Synbiotic Dual Cap® (1 capsule daily, taken in the morning without food) alongside their existing GLP-1 medication for 12 consecutive weeks.
Participants will complete study-specific questionnaires at four assessment timepoints: Baseline, Week 4, Week 8, and Week 12. No placebo control arm is included; all efficacy comparisons are within-subject against Baseline values. The study is conducted entirely remotely via the Citruslabs digital platform, with the study product shipped directly to participants' homes.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Dimitra Diamantopoulou
- E-mail: dimitra@epetome.com
Studiesteder
-
-
Nevada
-
Las Vegas, Nevada, Forenede Stater, 89101
- Citruslabs
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Adults aged 18-65 years.
- Have initiated a GLP-1 receptor agonist or dual-incretin medication for weight loss (including but not limited to semaglutide, tirzepatide, or liraglutide) within the last 60 days prior to the date of enrollment.
- Self-reported experience of at least one gastrointestinal symptom associated with GLP-1 initiation, including nausea, bloating, constipation, diarrhea, or general digestive discomfort, at the time of screening.
- Currently on a stable GLP-1 dose as directed by their prescribing physician.
- Willing to take one Synbiotic Dual Cap® daily for 12 consecutive weeks alongside their existing GLP-1 medication and complete all questionnaire assessments at Baseline, Week 4, Week 8, and Week 12.
- Willing and able to provide informed consent prior to enrollment.
- In good general health (GLP-1 use and associated weight-related conditions do not disqualify a participant).
- Reside in the United States.
Exclusion Criteria:
- Currently pregnant or breastfeeding (or planning to become pregnant during the study period).
- Currently taking other fibre, probiotic, prebiotic, or synbiotic supplements that cannot be discontinued for the study period.
- Diagnosed with a chronic gastrointestinal condition requiring active prescription medical management - including Crohn's disease, ulcerative colitis, coeliac disease, GERD, or gastroparesis - that would independently confound GI symptom endpoints.
- Use of antibiotics or prescription gastrointestinal medications within the past 30 days prior to enrollment, or intentions to use these medications during the study period.
- Anyone currently participating or planning to participate in another research study during the study period.
- Currently receiving immunosuppressant therapy of any kind.
- Currently undergoing cancer treatment or have had a serious illness requiring hospitalization in the last three months.
- Reside in Hawaii.
- Known allergy or hypersensitivity to any ingredient in the Synbiotic Dual Cap®.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Synbiotic Dual Cap® Arm
|
Participants will take 1 capsule each morning, without food and without a hot drink, for 12 consecutive weeks alongside their existing GLP-1 medication. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Overall Gastrointestinal Comfort
Tidsramme: Baseline to Week 12
|
Within-subject change from Baseline in overall gastrointestinal comfort severity, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Bowel Regularity
Tidsramme: Baseline to Week 12
|
Within-subject change from Baseline in bowel regularity, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Bloating
Tidsramme: Baseline to Week 12
|
Within-subject change from Baseline in bloating severity and frequency, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Constipation
Tidsramme: Baseline to Week 12
|
Within-subject change from Baseline in constipation severity and frequency, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Diarrhea
Tidsramme: Baseline to Week 12
|
Within-subject change from Baseline in diarrhea severity and frequency, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Nausea
Tidsramme: Baseline to Week 12
|
Within-subject change from Baseline in nausea severity and frequency, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Post-Meal Fullness Comfort
Tidsramme: Baseline to Week 12
|
Within-subject change from Baseline in comfort with post-meal fullness, assessed using study-specific questionnaires |
Baseline to Week 12
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Participant Perception of Effect on Overall Gastrointestinal Comfort
Tidsramme: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on overall gastrointestinal comfort, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Bowel Regularity
Tidsramme: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on bowel regularity, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Bloating
Tidsramme: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on bloating, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Constipation
Tidsramme: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on constipation, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Diarrhea
Tidsramme: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on diarrhea, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Nausea
Tidsramme: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on nausea, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Post-Meal Fullness Comfort
Tidsramme: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on post-meal fullness comfort, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i det endokrine system
- Ernæringsforstyrrelser
- Metaboliske sygdomme
- Overernæring
- Kropsvægt
- Tegn og symptomer, fordøjelsessystemet
- Glukosemetabolismeforstyrrelser
- Diabetes mellitus
- Overvægtig
- Patologiske tilstande, tegn og symptomer
- Ernæringsmæssige og metaboliske sygdomme
- Tegn og symptomer
- Fedme
- Diabetes mellitus, type 2
- Kvalme
- Forstoppelse
- Diarré
Andre undersøgelses-id-numre
- EPETO-21217
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .